Trial intelligence / Profile preview

HC1902 vs Cleviprex in hypertensive emergencies and urgencies

CTR20230762Phase 3Completed

Sponsor
CSPC Zhongnuo Pharmaceutical
Start
Mar 2023
Modality
Small Molecules
Countries
1
01

Overview

A Phase 3 trial of clevidipine in hypertensive emergency, hypertensive urgency, hypertension (HTN), sponsored by CSPC Zhongnuo Pharmaceutical. Started Mar 2023; status: completed.

02

Drugs

clevidipine
03

Conditions

hypertensive emergencyhypertensive urgencyhypertension (HTN)

Beyond the preview

Go deeper on CTR20230762.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on CTR20230762.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call